RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Core Viewpoint - RenovoRx, Inc. is increasing production of its FDA-cleared RenovoCath catheter-based delivery system due to rising demand from oncologists and interventional radiologists for targeted delivery of diagnostic and therapeutic agents [1] Group 1: Production and Manufacturing - RenovoRx has signed a new project work order with Medical Murray to expand their manufacturing relationship and explore commercial opportunities for RenovoCath beyond current clinical programs [2] - To incentivize Medical Murray, RenovoRx will issue a warrant for up to 709,500 shares of common stock, contingent on achieving certain manufacturing milestones [2] Group 2: Clinical Trials and Research - The company is committed to its ongoing pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer (LAPC), with additional clinical sites joining to accelerate patient enrollment [3] - The TIGeR-PaC trial is evaluating the TAMP™ therapy platform using RenovoCath for intra-arterial infusion of gemcitabine HCl, comparing it to the current standard of care [3][7] - The primary endpoint of the trial is a 6-month overall survival benefit, with secondary endpoints including reduced side effects compared to standard treatment [8] Group 3: Market Strategy and Leadership - Feedback from physicians indicates a desire to purchase RenovoCath as a standalone device, which has been used in over 500 procedures [4] - The company is exploring commercial opportunities to meet growing demand for RenovoCath technology and expects to generate revenue during 2025 [4] - Robert Strasser has been promoted to Vice President of R&D and Operations, playing a key role in the company's manufacturing and commercial strategy [4] Group 4: Product Information - RenovoCath is designed for the isolation of blood flow and delivery of fluids to selected sites in the peripheral vascular system, indicated for temporary vessel occlusion and chemotherapeutic drug infusion [5][9] - The device is intended for use in arteries with diameters ranging from 3mm to 11mm [5]